GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iBio Inc (AMEX:IBIO) » Definitions » ROA %

iBio (IBIO) ROA %

: -91.62% (As of Dec. 2023)
View and export this data going back to 2008. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. iBio's annualized Net Income for the quarter that ended in Dec. 2023 was $-32.84 Mil. iBio's average Total Assets over the quarter that ended in Dec. 2023 was $35.85 Mil. Therefore, iBio's annualized ROA % for the quarter that ended in Dec. 2023 was -91.62%.

The historical rank and industry rank for iBio's ROA % or its related term are showing as below:

IBIO' s ROA % Range Over the Past 10 Years
Min: -92.47   Med: -40.82   Max: -19.25
Current: -65.24

During the past 13 years, iBio's highest ROA % was -19.25%. The lowest was -92.47%. And the median was -40.82%.

IBIO's ROA % is ranked worse than
70.26% of 1557 companies
in the Biotechnology industry
Industry Median: -35.71 vs IBIO: -65.24

iBio ROA % Historical Data

The historical data trend for iBio's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iBio Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROA %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.76 -26.35 -19.25 -40.91 -92.47

iBio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -196.84 -60.67 -56.39 -58.27 -91.62

Competitive Comparison

For the Biotechnology subindustry, iBio's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iBio ROA % Distribution

For the Biotechnology industry and Healthcare sector, iBio's ROA % distribution charts can be found below:

* The bar in red indicates where iBio's ROA % falls into.



iBio ROA % Calculation

iBio's annualized ROA % for the fiscal year that ended in Jun. 2023 is calculated as:

ROA %=Net Income (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=-65.01/( (99.406+41.207)/ 2 )
=-65.01/70.3065
=-92.47 %

iBio's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-32.844/( (37.678+34.022)/ 2 )
=-32.844/35.85
=-91.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


iBio  (AMEX:IBIO) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-32.844/35.85
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-32.844 / 0)*(0 / 35.85)
=Net Margin %*Asset Turnover
=N/A %*0
=-91.62 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


iBio ROA % Related Terms

Thank you for viewing the detailed overview of iBio's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


iBio (IBIO) Business Description

Traded in Other Exchanges
N/A
Address
8800 HSC Parkway, Bryan, TX, USA, 77807-1107
iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: Biopharmaceuticals and Bioprocessing activities, conducted within iBio, Inc. and CDMO segment, conducted within iBio CDMO.
Executives
Martin Brenner officer: Chief Scientific Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Felipe Duran officer: Interim CFO 8800 HSC PARKWAY, BRYAN TX 77807
William D Clark director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Evert B. Schimmelpennink director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Isett Thomas Francis 3rd director, officer: CEO and Executive Chairman C/O IBIO INC. 600 MADISON AVENUE, SUITE 1601, NEW YORK NY 10022
Robert Matthew Lutz officer: See Remarks 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Randy Joe Maddux officer: Chief Operating Officer 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Alexandra Kropotova director RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Gary Sender director C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVE, NEW YORK NY 10020
Linda Washington Armstrong director 8800 HSC PARKWAY, BRYAN TX 77807
John Delta officer: Principal Accounting Officer 8800 HSC PARKWAY, BRYAN TX 77807
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Robert L Erwin officer: President C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
James P. Mullaney officer: Chief Financial Officer C/O IBIO, INC., 600 MADISON AVE., SUITE 1601, NEW YORK NY 10022
Carl Desantis 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431